Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 217297, 9 pages
http://dx.doi.org/10.1155/2013/217297
Research Article

In Vivo TLR9 Inhibition Attenuates CpG-Induced Myocardial Dysfunction

1Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
2Institute of Physiology II, University of Bonn, Nussallee 11, 53115 Bonn, Germany

Received 27 December 2012; Accepted 11 March 2013

Academic Editor: Freek Zijlstra

Copyright © 2013 O. Boehm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Mohan and J. Zhu, “Toll-like receptor signaling pathways—therapeutic opportunities,” Mediators of Inflammation, vol. 2010, Article ID 781235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. E. J. Seeley, M. A. Matthay, and P. J. Wolters, “Inflection points in sepsis biology: from local defense to systemic organ injury,” American Journal of Physiology, vol. 303, no. 5, pp. L355–L363, 2012. View at Google Scholar
  3. S. F. Ehrentraut, A. Dorr, H. Ehrentraut et al., “Vascular dysfunction following polymicrobial sepsis: role of pattern recognition receptors,” PloS One, vol. 7, no. 9, Article ID e44531, 2012. View at Google Scholar
  4. G. Plitas, B. M. Burt, H. M. Nguyen, Z. M. Bamboat, and R. P. DeMatteo, “Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis,” Journal of Experimental Medicine, vol. 205, no. 6, pp. 1277–1283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Parrillo, M. M. Parker, C. Natanson et al., “Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy,” Annals of Internal Medicine, vol. 113, no. 3, pp. 227–242, 1990. View at Google Scholar · View at Scopus
  6. S. L. Zanotti-Cavazzonia and S. M. Hollenberg, “Cardiac dysfunction in severe sepsis and septic shock,” Current Opinion in Critical Care, vol. 15, no. 5, pp. 392–397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Knuefermann, M. Schwederski, M. Velten et al., “Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of Toll-like receptor 9,” Cardiovascular Research, vol. 78, no. 1, pp. 26–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Hong, Z. Jiang, W. Liangxi et al., “Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release,” International Immunopharmacology, vol. 4, no. 2, pp. 223–234, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Yamada, K. J. Ishii, and D. M. Klinman, “Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung,” Critical Care Medicine, vol. 32, no. 10, pp. 2045–2049, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. F. J. Barrat, T. Meeker, J. Gregorio et al., “Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus,” Journal of Experimental Medicine, vol. 202, no. 8, pp. 1131–1139, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Sparwasser, T. Miethke, G. Lipford et al., “Bacterial DNA causes septic shock,” Nature, vol. 386, no. 6623, pp. 336–337, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Peter, K. Bode, G. B. Lipford, F. Eberle, K. Heeg, and A. H. Dalpke, “Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity,” Immunology, vol. 123, no. 1, pp. 118–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Velten, G. D. Duerr, T. Pessies et al., “Priming with synthetic oligonucleotides attenuates pressure overload-induced inflammation and cardiac hypertrophy in mice,” Cardiovascular Research, vol. 96, no. 3, pp. 422–432, 2012. View at Publisher · View at Google Scholar
  14. P. Knuefermann, G. Baumgarten, A. Koch et al., “CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo,” Respiratory Research, vol. 8, p. 72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Pacher, T. Nagayama, P. Mukhopadhyay, S. Bátkai, and D. A. Kass, “Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats,” Nature Protocols, vol. 3, no. 9, pp. 1422–1434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Ehrentraut, R. Meyer, M. Schwederski et al., “Systemically administered ligands of toll-like receptor 2, -4, and -9 induce distinct inflammatory responses in the murine lung,” Mediators of Inflammation, vol. 2011, Article ID 746532, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Sparwasser, T. Miethke, G. Lipford et al., “Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-α-mediated shock,” European Journal of Immunology, vol. 27, no. 7, pp. 1671–1679, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Krieg, A. K. Yi, S. Matson et al., “CpG motifs in bacterial DNA trigger direct B-cell activation,” Nature, vol. 374, no. 6522, pp. 546–549, 1995. View at Google Scholar · View at Scopus
  19. A. Kužnik, M. Benčina, U. Švajger, M. Jeras, B. Rozman, and R. Jerala, “Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines,” Journal of Immunology, vol. 186, no. 8, pp. 4794–4804, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Yasuda, A. Leelahavanichkul, S. Tsunoda et al., “Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury,” American Journal of Physiology, vol. 294, no. 5, pp. F1050–F1058, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. D. Pawar, A. Ramanjaneyulu, O. P. Kulkarni, M. Lech, S. Segerer, and H. J. Anders, “Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1721–1731, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. Zeuner, K. J. Ishii, M. J. Lizak et al., “Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides,” Arthritis and Rheumatism, vol. 46, no. 8, pp. 2219–2224, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. D. Halpern and D. S. Pisetsky, “In vitro inhibition of murine IFNγ, production by phosphorothioate deoxyguanosine oligomers,” Immunopharmacology, vol. 29, no. 1, pp. 47–52, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. D. S. Pisetsky and C. F. Reich, “Inhibition of murine macrophage IL-12 production by natural and synthetic DNA,” Clinical Immunology, vol. 96, no. 3, pp. 198–204, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. D. M. Klinman, D. Tross, S. Klaschik, H. Shirota, and T. Sato, “Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides,” Annals of the New York Academy of Sciences, vol. 1175, pp. 80–88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Shirota, I. Gursel, M. Gursel, and D. M. Klinman, “Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock,” Journal of Immunology, vol. 174, no. 8, pp. 4579–4583, 2005. View at Google Scholar · View at Scopus
  27. A. M. Avalos and H. L. Ploegh, “Competition by inhibitory oligonucleotides prevents binding of CpG to C-terminal TLR9,” European Journal of Immunology, vol. 41, no. 10, pp. 2820–2827, 2011. View at Publisher · View at Google Scholar
  28. R. F. Ashman, J. A. Goeken, E. Latz, and P. Lenert, “Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding,” International Immunology, vol. 23, no. 3, pp. 203–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. P. S. Lenert, “Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for toll-like receptors (TLR) 7 and 9,” Mediators of Inflammation, vol. 2010, Article ID 986596, 10 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. H. Boyd, “Toll-like receptors and opportunities for new sepsis therapeutics,” Current Infectious Disease Reports, vol. 14, no. 5, pp. 455–461, 2012. View at Publisher · View at Google Scholar
  31. Y. Feng, L. Zou, M. Zhang, Y. Li, C. Chen, and W. Chao, “MyD88 and Trif signaling play distinct roles in cardiac dysfunction and mortality during endotoxin shock and polymicrobial sepsis,” Anesthesiology, vol. 115, no. 3, pp. 555–567, 2011. View at Publisher · View at Google Scholar
  32. P. D. Annane, P. E. Bellissant, and J. M. Cavaillon, “Septic shock,” The Lancet, vol. 365, no. 9453, pp. 63–78, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Bennett-Guerrero, H. P. Grocott, J. H. Levy et al., “A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass,” Anesthesia and Analgesia, vol. 104, no. 2, pp. 378–383, 2007. View at Publisher · View at Google Scholar · View at Scopus